Series of renal cell carcinomas with TFE3 overexpression by copy number gains and without TFE3 gene rearrangement.

Abstract readCase Reports

In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Timothy Isaac MillerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. tisaac.miller@gmail.com.ORCID http://orcid.org/0009-0007-4733-4728

Maria TretiakovaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0819-9638

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case series describes four renal cell carcinomas (RCCs) with positive TFE3 protein expression by immunostain and only copy number gains detected by TFE3 fluorescence in situ hybridization without TFE3 rearrangement. Three of the four cases were diagnosed as clear cell RCC, and one was unclassified. All four cases were staged as pT3a on nephrectomy. Three of them were grade 4 and had documented metastases. This raises the possibility that RCC with TFE3 copy number gains in the absence of gene rearrangement may be a poor prognostic factor and reinforces that TFE3 immunostain cannot be used alone to diagnose TFE3-rearranged RCC.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsAdultDNA Copy Number VariationsFemaleGene DosageGene RearrangementHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorTFE3 protein, humanCopy number gainRenal cell carcinomaTFE3

Identifiers

PMID41212280

DOI10.1007/s00428-025-04323-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.